

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE, THE NOMINATION COMMITTEE AND THE REMUNERATION AND APPRAISAL COMMITTEE

References are made to the announcement of Suzhou Basecare Medical Corporation Limited (the “**Company**”) dated June 20, 2023 and the circular of the Company dated June 28, 2023 (the “**Circular**”) in relation to the appointment of Mr. LAM Siu Wing (“**Mr. Lam**”) as an independent non-executive director of the Company, the chairman of the audit committee (the “**Audit Committee**”), and a member of each of the nomination committee (the “**Nomination Committee**”) and the remuneration and appraisal committee (the “**Remuneration and Appraisal Committee**”) of the Company.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the resolution regarding the appointment of Mr. Lam as an independent non-executive Director was approved at the 2023 first extraordinary general meeting of the Company (the “**EGM**”) held on July 13, 2023. The appointment of Mr. Lam as an independent non-executive Director has become effective on the date of the EGM, being July 13, 2023. Poll results of the EGM are set out in the poll results announcement of the Company dated July 13, 2023.

The biographical details and other relevant information regarding Mr. Lam are set out in the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company has entered into a letter of appointment with Mr. Lam in relation to his appointment as an independent non-executive Director for a term commencing from the date of approval of his appointment at the EGM, being July 13, 2023, and expiring on the conclusion of the first session of the Board of Directors. This term of office is terminable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Under the terms of the letter of appointment, Mr. Lam will be entitled to an annual director fee of HK\$200,000 (before tax). The remuneration of Mr. Lam is determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Mr. Lam has not entered into nor proposed to enter into any service contracts, which fall within the meanings of Rule 13.68 of the Listing Rules requiring the prior approval of shareholders of the Company at general meetings, with the Company.

Save as disclosed above, there is no other matter concerning Mr. Lam's appointment that needs to be brought to the attention of the shareholders of the Company.

CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE, THE NOMINATION COMMITTEE AND THE REMUNERATION AND APPRAISAL COMMITTEE

The Board is pleased to announce that, following the resolution regarding the appointment of Mr. Lam as an independent non-executive Director being passed at the EGM, with effect from July 13, 2023, Mr. Lam has been appointed as the chairman of the Audit Committee and a member of each of the Nomination Committee and the Remuneration and Appraisal Committee. Following the above appointments, the composition of the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee are as follows: (1) the Audit Committee comprises two independent non-executive Directors, namely Mr. Lam (chairman of the Audit Committee) and Dr. KANG Xixiong, and one non-executive Director, namely Mr. WANG Weipeng; (2) the Nomination Committee comprises two independent non-executive Directors, namely Dr. KANG Xixiong and Mr. Lam, and one executive Director, namely Dr. LIANG Bo (chairman of the Nomination Committee); and (3) the Remuneration and Appraisal Committee comprises two independent non-executive Directors, namely Dr. KANG Xixiong (chairman of the Remuneration and Appraisal Committee) and Mr. Lam, and one executive Director, namely Dr. LIANG Bo.

The Board would like to take this opportunity to extend a warm welcome to Mr. Lam for joining the Board. Following the appointment of Mr. Lam, the Company has re-complied with the requirements under Rules 3.10, 3.10A, 3.21, 3.25, 3.27A, 19A.18(1) of the Listing Rules, the requirement under article 3 of the terms of reference of the Audit Committee, the requirement under article 4 of the terms of reference of the Remuneration and Appraisal Committee and the requirement under article 3 of the terms of reference of the Nomination Committee.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, July 13, 2023

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. LAM Siu Wing as independent non-executive Directors.